Influence of Long-term Abemaciclib, A New CDK 4/6 Inhibitor: Decrease in Liver Metastasis in a Patient Suffering from Metastatic Breast Cancer

Abstract

An 82-year old patient suffering from metastatic breast cancer (FIGO IV D) underwent surgical operations and radiation treatments in the past. From November 29, 2018 until now, the patient was treated with 100 mg Abemaciclib (2 x 50 mg). During therapy, her pain subjectively decreased. No relevant side effects were observed. After 6 months, hepatic metastasis was checked by means of computer tomograph (CT) and a significant reduction of metastasis size was documented.